Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the belgian health care authorities

Acta Clinica Belgica

Volumn 64, Issue 2, 2009, Pages 100-112

  Vlaenderen, I Van ^a   Canon, J L ^b   Cocquyt, V ^c   Jerusalem, G ^d   Machiels, J P ^e   Neven, P ^f   Nechelput, M ^g   Delabaye, I ^g   Gyldmark, M ^h   Annemans, L ⁱ  

^a Deloitte Life Sciences Industry Consulting   (Belgium)

^b Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Roche Pharmaceuticals   (Belgium)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ GHENT UNIVERSITY   (Belgium)

Author keywords

Belgium; Cost effectiveness; Early stage breast cancer; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BELGIUM; BREAST CANCER; BUDGET; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; HEART DISEASE; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RISK REDUCTION; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BELGIUM; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MORBIDITY; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 64949089176     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Van Eycken E, De Wever N. Cancer Incidence and Survival in Flanders, 2000-2001. Flemish Cancer Registry Network, VLK, Brussels, 2006.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
3. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.J Clin Oncol 1992; 10:1044-8.
4. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.J Clin Oncol 2005;23:2162-71.
5. Ross JS, Fletcher JA. The HER-2/Neu oncogene, in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 1998;16:413-28.
6. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005; 23:4265-74.
7. NICE. Improving Outcomes in Breast Cancer. National Institute for Clinical Excellence, London, 2002.
8. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005;353:1784-92.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. New Engl J Med 2005; 353:1659-72.
10. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369:29-36.
11. Romond EH, Perez EA, Bryant J, et al.Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. New Engl J Med 2005; 353:1673-84.
12. Bell R, Gianni L, Cameron DA, et al. Modelling predicts a long-term benefit from trastuzumab (Herceptin®) use in HER2-posi-tive breast cancer. Ann Oncol 2006; 17 (suppl. 9), abstr. 247PD.
13. Wardley AM, Cameron DA, Bell R, et al. Cost-effectiveness analysis of adjuvant therapy with trastuzumab (Herceptin®) for early breast cancer. Ann Oncol 2006; 17 (suppl. 9), abstr. 248PD.
14. KCE-Federaal Kenniscentrum voor de gezondheidszorg / Centre federal d'expertise des soins de sante (Belgium):Trastuzum-ab in Early Stage Breast Cancer. KCE reports vol. 34C, 2006.
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast ancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
16. NIS-National Institute of Statistics, Belgian Federal Public Service Economy, SMEs, Self-employed and Energy, 2005. Available at: http://www.statbel.fgov.be/.
17. NICE. Final appraisal Determination: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. June 2006.
18. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Medical Care 2000; 38: 583-637.
19. Hayman JA, Hillner BE, Harris JR, Weeks JC.The cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer, J Clin Oncol 1998; 16:1022-9.
20. Carter KJ, Ritchey NP, Castro F, et al. Treatment of early-stage breast cancer in the elderly: a health outcome-based approach. Med Decis Making 1998; 18: 213-9.
21. Hillner B, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. New Eng J Med 1991; 324:160-8.
22. International Classification of Diseases, 9th edition, Clinical Modification (ICD 9-CM).
23. Pirson M, Dramaix M, Leclercq P, Jackson T. Analysis of cost outliers within APR-DRGs in a Belgian general hospital: Two complementary approaches. Health Policy 2005; 76:13-25.
24. WHO-World Health Organization Collaborating Centre for Drug Statistics Methodology, 2005. Available at: http://www.whocc.no/atcddd/. Accessed December 7,2005.
25. TC-Technical Cell of the Belgian Federal Ministry of Social Affairs, Public Health and Environment, 2005. Available at: https://tct.fgov.be/etct/ index.html.
26. RIZIV/INAMI-Rijksinstituut voor ziekte-en invaliditeitsverze-kering / Institut national d'assurance maladie invalidite. Available at: http://inami.fgov.be/homefr.htm.
27. CECODI. Studiecentrum voor Coordinate en Verspreiding-Tarifering van de Geneeskundige Verstrekkingen 2006.
28. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 (Suppl), S111-6.
29. NICE. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. November 2006.
30. Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium. Health Policy 2008; doi:10.1016/j.health-pol.2007.11.003.
31. Manca A, Willan AR. 'Lost in Translation' Accounting for Between-Country Differences in the Analysis of Multinational Cost-Effectiveness Data. Pharmacoeconomics 2006; 26: 1101-19.
32. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008; 19:487-95.
33. Norum J, Olsen JA, Wist EA, Lonning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol 2007; 46:153-64.
34. Dedes KJ, SzucsTD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2007; 18:1493-9.
35. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. V Clin Oncol 2007; 25:625-33.
36. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 2007; 25: 611-3.
37. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007; 110: 489-98.
38. Kurian AW, Thompson RN, GawAF.Arai S, Ortiz R, GarberAM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer, J Clin Oncol 2007; 25: 634-41.
39. Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 2008; DOI 10.1007/s10549-007-9679-4.
40. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer. Pharmacoeconom-ics 2007; 25:429-42.
41. Takita M, Matsumura T, Kodama Y, Tanaka Y, Kami M. Trastuzumab after adjuvant chemotherapy in older patients. Lancet 2007; 369: 991-2.
42. Piccart-Cebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer 2006; 42:1715-9.
43. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20.
44. Stemmler HJ, Schmitt M,Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-pos-itive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18: 23-8.
45. Bernard-Marty C, Lebrun F, Awada A, Piccart MJ. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006; 66:1577-91.
46. Giuliani R, Durbecq V, Di Leo A, et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007; 43: 725-35.